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Abstract
The regulator of G-protein signaling (RGS) pathway plays an important role in signaling transduction, cellular activities, and
carcinogenesis. We hypothesized that genetic variations in RGS gene family may be associated with the response of late-
stage non-small cell lung cancer (NSCLC) patients to chemotherapy or chemoradiotherapy. We selected 95 tagging single
nucleotide polymorphisms (SNPs) in 17 RGS genes and genotyped them in 598 late-stage NSCLC patients. Thirteen SNPs
were significantly associated with overall survival. Among them, rs2749786 of RGS12 was most significant. Stratified analysis
by chemotherapy or chemoradiation further identified SNPs that were associated with overall survival in subgroups.
Rs2816312 of RGS1 and rs6689169 of RGS7 were most significant in chemotherapy group and chemoradiotherapy group,
respectively. A significant cumulative effect was observed when these SNPs were combined. Survival tree analyses identified
potential interactions between rs944343, rs2816312, and rs1122794 in affecting survival time in patients treated with
chemotherapy, while the genotype of rs6429264 affected survival in chemoradiation-treated patients. To our knowledge,
this is the first study to reveal the importance of RGS gene family in the survival of late-stage NSCLC patients.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer mortality worldwide [1]. Over 45% of NSCLC patients
present with unresectable late-stage (stage IIIA/B or stage IV)
disease in the United States [2]. A combined modality therapy is
the current standard of care for patients with stage III NSCLC
with good performance status (performance score 0 or 1).
Numerous clinical trials have shown that concurrent chemoradia-
tion offers a significant survival advantage over sequential
chemoradiation [3]. Although concurrent chemoradiotherapy
significantly improves the survival of patients with locally
advanced disease, the majority of patients still die within 5 years
because of locoregional or distant disease progression [4]. The
stage IV patients are usually offered palliative chemotherapy and
supportive care [5]. There is a wide variability in patients’
response to chemoradiation and clinicopathological variables
alone do not provide satisfactory guidance for the decision of
treatment strategy. The application of pharmacogenomics may
improve the prediction of response and help clinicians determine
cancer treatments for individual NSCLC patient according to his
unique genetic background. Therefore, in this study, we aimed to
identify genetic predictors for clinical outcomes of late stage
NSCLC patients.
G proteins (guanine nucleotide-binding proteins) are important
cellular signal transduction molecules that are expressed in all
human cells [6,7]. They are activated by G protein-coupled
receptors (GPCRs) and thereby may transduce extracellular signals
into the interior of a cell [8]. GPCRs are a family of seven-
transmembrane domain receptors. When GPCRs traduce a signal
inside the cell, the extracellular domain of GPCR first binds to the
signal molecules, and then the intracellular domain of GPCR
activates a heterotrimeric G-protein. The heterotrimeric G protein
functions as ‘‘molecular switches’’ and can activate a cascade of
signaling factors and downstream target activation [7]. This G
protein-coupled biological process requires fine-tuning through
accessory molecules such as the regulator of G-protein signaling
(RGS) [9]. RGS proteins are a big family of over 30 intracellular
proteins [10], which can negatively modulate GPCRs signaling
pathways [11,12]. RGS are multi-functional, GTPase-accelerating
proteins that promote GTP hydrolysis by the alpha subunit of
heterotrimeric G proteins, thereby inactivating the G protein and
rapidly switching off GPCR signaling pathways[11]. All RGS
proteins contain a RGS domain (also referred as ‘‘RGS-box’’)
,which is required for their activities [13], and these RGS domains
mediate the interaction with other signaling proteins, allowing RGS
proteins to serve as signaling scaffolds [8]. Malfunctions of RGS
proteins have been reported to be related to the pathogenesis of
many common human diseases and drug addiction [14,15,16,17].
Multiple RGS proteins were found differentially expressed in a
variety of solid and hematological malignancies[18,19,20,21,22,
23,24,25,26,27,28,29,30,31,32,33,34,35,36].
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associated with several human diseases, suggesting that genetic
variation in the RGS pathway may play a significant role in these
diseases’ pathogenesis [37,38]. Recently, RGS SNPs have also
been reported to play important roles in lung cancer. For instance,
SNPs in RGS17 on chromosome 6q23-25 was associated with
familial lung cancer susceptibility [39]. SNPs in RGS2 and RGS6
may modulate the risks of bladder and lung cancers [37,40].
Whether genetic variants in the RGS pathway could influence
clinical outcomes in patients with NSCLC remains unknown. In
this study, we tested the hypothesis that genetic variations of RGS
are associated with the survival of late-stage NSCLC patients
receiving chemotherapy or chemoradiation.
Results
We included 598 NSCLC patients in this study, with a mean
age of 59.7 years (Table 1). Of the 598 patients, 456 were dead
and 142 were alive. We found no significant difference in age
(P=0.884), ethnicity (P=0.937), smoking status (P=0.860), and
pack-years of smoking (P=0.926) between the two groups of
patients (Table 1). However, we observed a significant difference
in mortality status by gender (P=0.002), clinical stage (P=0.004),
and performance status (P=0.002) (Table 1).
Associations between SNPs and overall survival in late-
stage NSCLC patients
A total of 13 SNPs in 6 genes were significantly associated with
the risk of death at P,0.05 (Table 2). Among them, the variant
alleles of four SNPs, rs7549021 and rs1056515 of RGS5, rs944343
of RGS3, and rs2749786 of RGS12, were associated with decreased
risks of death, with adjusted HRs of 0.42 (95% CI, 0.22 to 0.83),
0.72 (95% CI, 0.54 to 0.97), 0.80 (95% CI, 0.67 to 0.95), and 0.58
(95% CI, 0.40 to 0.85), respectively. Other SNPs conferred
increased risks of death. All SNPs in the RGS1 gene were in linkage
disequilibrium (with r
2.0.8) with similar HRs in a dominant
model.
The bootstrap re-sampling analysis was then performed for the
13 SNPs to internally validate the results. We found that only 5
SNPs, rs944343 (RGS3), rs6678136 (RGS4), rs7549021 (RGS5),
rs3820487 (RGS5), and rs2749786 (RGS12), had bootstrap P values
,0.05 at least 70 times out of 100 times (Table 2). The other
SNPs had bootstrap P values ,0.05 less than 50 times, indicating
that those SNPs were likely false-positive results.
Associations between SNPs and risk of death stratified by
treatment
We then performed a stratified analysis by treatment modality,
chemotherapy or chemoradiation (Tables 3 and 4). Nine SNPs
were associated with overall survival in patients who received
chemotherapy only, 5 of which had bootstrap P values ,0.05 at
least 70 times out of 100 times (Table 3). Among these five SNPs,
three (rs2816312 [RGS1], rs10218752 [RGS5], and rs1122794
[RGS11]) were associated with an increased risk of death, with
HRs of 1.80 (95% CI, 1.32 to 2.45), 1.76 (95% CI, 1.06 to 2.90),
and 1.37 (95% CI, 1.07 to 1.77), respectively. On the other hand,
rs944343 (RGS3) and rs1051013 (RGS3) were associated with a
decreased risk of death, with HRs of 0.73 (95% CI, 0.57 to 0.94)
and 0.77 (95% CI, 0.60 to 0.98), respectively. In Kaplan-Meier
analyses, four of the five significant SNPs (rs2816312 [RGS1],
rs944343 [RGS3], rs1051013 [RGS3], and rs1122794 [RGS11])
were significantly associated with altered median-survival time
(MST) (log-rank P value ,0.05) (Table 3).
There were eight SNPs significantly associated with survival
status in patients who received chemoradiation, five of which had
bootstrap P values ,0.05 more than 70 times out of 100 times
(Table 4). Among these five SNPs, three (rs2344673 [RGS5],
rs12127281 [RGS5], and rs6429264 [RGS7]) were associated with
an increased risk of death, with HRs of 1.86 (95% CI, 1.00 to
3.47), 1.83 (95% CI, 1.09 to 3.10), and 1.89 (95% CI, 1.06 to
3.38), respectively; while rs12757054 (RGS7) and rs6689169
(RGS7) were associated with a decreased risk of death, with HRs
of 0.48 (95% CI, 0.26 to 0.86) and 0.47 (95% CI, 0.27 to 0.80),
respectively. Two of these 5 SNPs on RGS7 (rs6429264 and
rs6689169) were associated with altered MST for NSCLC patients
(log-rank P=0.0055 and 0.0441, respectively) (Table 4).
Cumulative effects of the unfavorable genotypes on
survival
We further assessed the cumulative effects of the unfavorable
genotypes in either treatment groups using the SNPs with
bootstrap P values ,0.05 at least 70 times out of 100 times in
each group (Table 5). There were significant gene-dose effects in
patients receiving both treatments (Table 5). In those patients
receiving chemotherapy only and taking the low-risk reference
Table 1. Distribution of demographic and clinical variables by
survival status.
Variable Dead (n=456) Alive (n=142) P value*
Number (%) Number (%)
Gender
Men 262 (81.11) 61 (18.89)
Women 194 (70.55) 81 (29.45) 0.002
Ethnicity
Caucasian 358 (76.17) 112 (23.83)
African American 72 (75.79) 23 (24.21)
Other 26 (78.79) 7 (21.21) 0.937
Smoking status
Never smoker 84 (75.00) 28 (25.00)
Former smoker 184 (74.72) 59 (24.28)
Current smoker 188 (77.37) 55 (22.63) 0.860
Clinical stage
IIIA 57 (69.51) 25 (30.49)
IIIB (Dry) 100 (70.42) 42 (29.58)
IIIB (Wet) 25 (60.10) 14 (35.90)
IV 274 (81.79) 61 (18.21) 0.004
Performance status
0 96 (67.13) 47 (32.87)
1 254 (76.05) 80 (23.95)
2-4 66 (89.19) 8 (10.81) ,0.002
Therapy
Chemotherapy 295 (64.69) 60 (16.90)
Chemoradiotherapy 104 (76.47) 32 (23.53)
Both 57 (53.27) 50 (46.73) ,0.001
Age, years (mean6SD)59.7610.6 59.6610.0 0.884
Pack-years (mean6SD)36.6630.4 36.9631.3 0.926
*Significant P values are in bold font.
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Gene and
SNPs
No. of
Dead/Alive
HR*
(95% CI) Smallest P MST
Log-rank
P value
No. of times in boot-
strap samples P,0.05
RGS3
rs944343
& 99
GG 274/77 Reference 11.68
CG 158/60 0.78 (0.63–0.97) 0.022435 14.21
CC
Trend
24/5 0.69 (0.43–1.10)
0.80 (0.67–0.95)
0.118902
Ptrend=0.011796
18.29 0.1278
RGS4
rs6678136
& 90
GG/GA 363/120 Reference 13.45
AA 93/22 1.36 (1.07– 1.73) 0.012744 10.92 0.0364
RGS5
rs7549021
& 93
AA/AG 444/132 Reference 12.83
GG 12/10 0.42 (0.22–0.83) 0.012568 24.51 0.0647
rs3820487
& 95
CC/CA 431/141 Reference 13.45
AA 25/1 1.81 (1.09–3.01) 0.022834 9.57 0.0001
rs1056515 28
CC/CA 395/119 Reference 12.86
AA 61/23 0.72 (0.54–0.97) 0.027911 13.62 0.1242
RGS12
rs2749786
& 100
AA/AG 425/125 Reference 12.70
GG 31/17 0.58 (0.40–0.85) 0.005532 26.84 0.0015
RGS22
rs2453627 41
CC 133/52 Reference 15.43
CG/GG 323/90 1.26 (1.01–1.56) 0.039106 12.04 0.0247
RGS1
rs2760535
# 47
GG 348/111 Reference 13.59
GA/AA 108/31 1.31 (1.02–1.67) 0.031854 10.72 0.1558
rs1323291
# 11
AA 347/110 Reference 13.59
AC/CC 109/33 1.28 (1.00–1.65) 0.049051 10.72 0.2181
rs16834456
# 47
CC 348/111 Reference 13.59
CA/AA 108/31 1.31 (1.02–1.67) 0.031854 10.72 0.1558
rs9427560
# 47
AA 348/111 Reference 13.59
AG/GG 108/31 1.31 (1.02–1.67) 0.031854 10.72 0.1558
rs2816310
# 11
CC 347/110 Reference 13.59
CA/AA 109/33 1.28 (1.00–1.65) 0.049051 10.72 0.2181
rs2816311
# 11
AA 347/110 Reference 13.59
AG/GG 109/33 1.28 (1.00–1.65) 0.049051 10.72 0.2181
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or 2 unfavorable genotypes) and the high-risk groups (3 or 4
unfavorable genotypes) had 1.69-fold (95% CI, 1.19 to 2.41;
P=0.004) and 2.52-fold (95% CI, 1.71–3.71; P,0.001) increased
risk of death, respectively (P for trend ,0.001). The MST for the
medium-risk and the high-risk groups were 11.22 months and 8.19
months, respectively, compared to 18.22 months for the low-risk
reference group (log-rank P value ,0.0001). Similar dose-response
trends were observed among patients receiving chemoradiation
(Table 5 and Figure 1).
Higher-order gene-gene interactions
The results of STREE program analysis for the interaction of
the 10 bootstrap-validated significant SNPs (the SNPs which had
#Linkage SNPs.
Abbreviations: SNPs, single nucleotide polymorphism; No., number; HR, hazard ratio; CI, confidence interval;
MST, median survival time.
&SNPs which had bootstrap P values ,0.05 at least 90% of times.
*HR adjusted by age, gender, ethnicity, smoking status and pack-years, performance status, clinical stage, and treatments.
doi:10.1371/journal.pone.0021120.t002
Table 2. Cont.
Table 3. Stratified analysis by treatment modality: Chemotherapy.
SNPs Gene
No. of
Dead/Alive
HR*
(95%CI) Smallest P MST
Log-rank
P value
No. of times in Boot-
strap samples P,0.05
rs2816312
& RGS1 100
AA 229/48 Reference 11.64
AG/GG 66/12 1.80 (1.32–2.45) 0.000199 8.16 0.0134
rs944343
& RGS3 99
GG 178/30 Reference 9.44
GC/CC 117/30 0.73 (0.57–0.94) 0.013565 12.76 0.0009
rs1051013
& RGS3 70
GG 186/33 Reference 9.57
GA/AA 109/27 0.77 (0.60–0.98) 0.03534 12.70 0.0147
rs10218752
& RGS5 97
AA/AG 278/59 Reference 10.92
GG 17/1 1.76 (1.06–2.90) 0.027803 9.01 0.0861
rs1122794
& RGS11 96
CC 193/48 Reference 11.55
CA/AA 102/12 1.37 (1.07–1.77) 0.013747 9.47 0.0249
rs12339493 RGS3 38
GG 239/43 Reference 10.53
GA/AA 56/17 0.73 (0.53–0.99) 0.043020 12.40 0.0311
rs7549021 RGS5 0
AA/AG 286/58 Reference 10.72
GG 9/2 0.42(0.22–0.83) 0.013 9.57 0.6077
rs2749786 RGS12 4
AA/AG 277/54 Reference 10.66
GG 18/6 0.60 (0.37–1.00) 0.049813 11.71 0.015
rs594149 RGS16 42
CC 205/35 Reference 10.59
CG/GG 90/25 0.80 (0.61–1.04) 0.0984 11.71 0.0467
P for trend 0.0446
AA/AG 102/30 Reference 16.58
GG 2/2 0.10 (0.01–0.78) 0.027524 24.51 0.0987
Abbreviations: SNPs, single nucleotide polymorphism; No., number; HR, hazard ratio; CI, confidence interval; MST, median survival time.
&SNPs which had bootstrap P values ,0.05 at least 70% of time.
*HR adjusted by age, gender, ethnicity, smoking status and pack-years, performance status, clinical stage.
#MST, median survival time (months).
doi:10.1371/journal.pone.0021120.t003
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in stratified analysis were presented in Figure 2. Survival tree
analysis resulted in four terminal nodes in the chemotherapy
group and two terminal nodes in the chemoradiation group
(Figure 2A). In the chemotherapy group, the initial split was
rs944343 (RGS3), and subsequent splits were rs2816312 (RGS1)
and rs1122794 (RGS11). Different nodes had different percentages
of death event. To assess the risk associated with each of the
terminal nodes, node 1 in the chemotherapy branch was taken as
the reference group, composed of individuals with the heterozy-
gous and the homozygous variant genotypes of rs944343 (RGS3)
and the homozygous wild-type genotype of rs1122794 (RGS11).
Compared with the reference group, patients in the terminal nodes
in the chemotherapy group had HRs ranging from 1.49 to 2.92.
Patients in node 1 had the longest MST of 13.58 months. The
highest at-risk group (node 3), which was composed of patients
carrying the homozygous wild-type genotype of rs944343 (RGS3)
and variant-containing genotypes of rs2816312 (RGS1), had a HR
of 2.92 (95% CI, 1.92 to 4.44). The MSTs were shown to be
significantly different in Kaplan-Meier survival analysis (log-rank P
value ,0.0001) (Figure 2B and Table 6). In the chemoradiation
group, there was only one additional split. Compared to the
patients with the homozygous wild-type genotype of rs6429264
(RGS7) (node 5), who had an MST of 19.28 months, the patients
carrying variant-containing genotypes of rs6429264 (RGS7)
exhibited a 1.89-fold increased risk of death (95% CI, 1.06 to
3.38), with an MST of 12.37 months (Figure 2C and Table 6).
Discussion
In this study, we found that genetic variations in RGS genes
were associated with overall survival in late-stage NSCLC patients.
Our findings also reinforced the importance of evaluating the
cumulative and interaction effects of genetic variations when
predicting clinical outcomes of patients with NSCLC.
NSCLC patients are mostly treated with the platinum-based
chemotherapy, often in combination with radiation therapy. The
platinum-based chemotherapy may be related to several cellular
pathways, such as the DNA damage/repair, cell cycle control, and
apoptosis pathways [41]. However, there has been no study
reporting that RGS is involved in the platinum-based chemother-
apy related pathways.
NSCLC cells can invade adjacent tissues and metastasize to
nonadjacent organs and tissues, processes that may be attrib-
uted to altered cellular signaling pathways [42,43]. Oncogenic
transformation is often the direct result of mutations of the
signaling molecules, which constitute these pathways. In this study,
5 SNPs were associated with the overall risk of death with
Table 4. Stratified analysis by treatment modality: Chemoradiation.
SNPs Gene
No. of
Dead/Alive
HR*
(95%CI) Smallest P MST
Log-rank
P value
No. of times in Boot-
strap samples P,0.05
rs2344673
& RGS5 88
GG 79/28 Reference 17.86
GA/AA 25/4 1.86 (1.00–3.47) 0.049508 11.48 0.1024
rs12127281
& RGS5 86
GG 59/25 Reference 19.14
GA/AA 45/7 1.83 (1.09–3.10) 0.023387 12.30 0.0602
rs12757054
& RGS7 73
GG 86/24 Reference 15.89
GA/AA 18/8 0.48 (0.26–0.86) 0.013902 24.51 0.2311
rs6429264
& RGS7 90
GG 82/28 Reference 19.28
GA/AA 22/4 1.89 (1.06–3.38) 0.031160 12.37 0.0055
rs6689169
& RGS7 96
AA 78/18 Reference 13.22
AG/GG 26/14 0.47 (0.27–0.80) 0.005776 24.51 0.0441
rs11586945 RGS5 3
GG 64/24 Reference 19.67
GC/CC 40/8 1.63 (1.02–2.61) 0.040998 12.53 0.0623
rs2999966 RGS5 0
CC/CA 96/27 Reference 16.05
AA 8/5 0.38 (0.15–0.99) 0.047362 35.92 0.0642
rs7549021 RGS5 0
AA/AG 102/30 Reference 16.58
GG 2/2 0.10 (0.01–0.78) 0.027524 24.51 0.0987
Abbreviations: SNPs, single nucleotide polymorphism; No., number; HR, hazard ratio; CI, confidence interval; MST, median survival time.
&SNPs which had bootstrap P values ,0.05 at least 70% of time.
*HR adjusted by age, gender, ethnicity, smoking status and pack-years, performance status, clinical stage.
#MST, median survival time (months).
doi:10.1371/journal.pone.0021120.t004
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of these 5 SNPs, rs6678136 (RGS4), rs3820487 (RGS5) and
rs2749786 (RGS12) conferred significantly different MST in
Kaplan-Meier curve (Table 4). Previous studies reported that
RGS4 gene expression were associated with invasion of several
cancer [36,44]. In addition, RGS4 protein acts as an inhibitor of
epithelial and endothelial cell tubulogenesis by regulating mitogen-
activated protein kinases and vascular endothelial growth factor
signaling, thereby inhibiting cell proliferation, migration, and
invasion [45]. Xiao et a.l reported that multiple SNPs in
combination in RGS5 may confer risk for hypertension in Chinese
population [46]. RGS5 was reported to be a key modulator of
tumor pericyte maturation and play a pivotal role in tumor
neovascularization [9]. RGS5 knockout mice showed larger tumor
burden and earlier death which may be caused by pericyte
maturation and vascular normalization [33]. RGS5 has also been
identified as a broadly expressed tumor antigen in multiple types of
cancer [47]. RGS12 is a large RGS protein with multiple
functional domains such as PDZ, PTB (phospho-tyrosine binding)
and Rap binding domains [48]. PDZ domain of RGS12 interacts
with a GPCR, CXCR2, and thereby contributes to the GAP
action of RGS12 on CXCR2-mediated G-protein signals [49].
Therefore, it is biologically plausible that RGS4, RGS5, and
RGS12 are associated with lung cancer survival. The functions of
the significant SNPs on these genes are not clear since they are
most likely tagging SNPs. Future studies are needed to find the
causal SNPs.
In stratified analyses, 5 SNPs in the chemotherapy group and
another 5 in the chemoradiation group were associated with the
risk of death with bootstrap P values ,0.05 at least 70 times out of
100 times. The genotypes of four SNPs: rs2816312 (RGS1),
rs944343 (RGS3), rs1051013 (RGS3), and rs1122794 (RGS11) were
found to be significantly associated with MST in chemotherapy
group. The most significant one was rs944343 (Log-rank
P=0.0009), which was a tagging SNP located at the 39 flanking
region of RGS3. Increased RGS3 expression has been used as a
diagnostic marker for soft tissue sarcoma and was associated with
resistance to chemotherapy in breast cancer [50,51]. In addition,
RGS3 has been reported to modulate glioma cell mobility [36].
The other host genes of SNPs in chemotherapy group, RGS1, and
RGS11, have also been associated with the etiology and prognosis
of cancer. Rangel et al. reported that RGS1 may be a prognostic
marker in melanoma progression and its expression was associated
with survival for melanoma patients [20]. Martinez-Cardus, et al.
reported that RGS11 expression was significantly associated with
the resistance to platinum therapy in colorectal cancer [52]. These
studies support the role of RGS1, RGS3, and RGS11 in lung
cancer prognosis. There were only two SNPs in chemoradiation
group, rs6429264 and rs6689169, significantly associated with
MST (log-rank P=0.0055 and 0.0441, respectively). both of which
are tagging SNP and located in RGS7. Several studies demon-
strated that tumor necrosis factor-a, a major inflammation
cytokine that plays an important role in many human cancers,
can rapidly activate the expression level of RGS7 [53,54]. The
mechanisms by which these genotypes determine their phenotypes
and affect the outcome of NSCLC are not clear. Further studies
are warranted to identify the causal variants and the biologic
mechanisms underlying our observed associations.
We also observed cumulative effects of RGS SNPs on the
survival of late-stage NSCLC patients. In addition, we used
survival tree analysis to identify interactions among these SNPs.
These gene-gene interactions resulted in four terminal nodes with
different risks of death in the chemotherapy-only group and two
terminal nodes with different risks of death the chemoradiation
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may allow us to identify more powerful prognostic or predictive
markers and signatures based on the combination of each patient’s
genetic variations. It should be noted that these types of analyses
were exploratory, and the results need to be validated in
independent studies.
There are a few strengths to our study. First, our current
pathway-based approach is a logical extension of the candidate
gene approach and avoids the requirement of much larger sample
size by genome-wide association study. Second, we have collected
a relative large population of NSCLC patients from the same
institution. The uniform standard operation procedures in the
cancer identification, pathological staging, and even strategy
determination for cancer treatment made our findings more
comprehensive and applicable to future clinical studies. Third, we
have performed internal statistical validation by a bootstrap
resampling procedure to minimize false discoveries. Fourth, we
have performed exploratory gene-gene interaction analysis to
establish a novel combination of SNPs to predict the outcome of
NSCLC patients for their therapy, which could help clinicians in
determining the optimal personalized treatment and the quality of
care for survival.
To the best of our knowledge, this is the first study investigating
the association of genetic variations in RGS family with survival
for NSCLC. Our results have provided not only SNP-based
analysis, but also a more comprehensive pathway-based approach
in the clinical outcome prediction for NSCLC patients who
underwent chemotherapy or chemoradiation. Future independent
validation in larger population and detailed functional assays are
necessary before these findings can be translated to the clinics.
Methods
Ethics Statement
All patients signed a written informed consent and this study has
been reviewed and approved by the Institutional Review Board
(IRB) of MD Anderson.
Study population and collection of epidemiologic and
clinical data
A total of 598 patients with late-stage NSCLC, including stages
IIIA, IIIB (Dry), IIIB (Wet), and IV, recruited between 1995 and
2007 from an epidemiological lung cancer study being conducted at
The University of Texas MD Anderson Cancer Center. None of
them had been previously treated by surgery chemotherapy, and/or
radiotherapy before enrollment into the study. All participants had
completed a risk factor questionnaire that collected data on
demographic characteristics, tobacco use history, occupational and
environmental exposures, prior medical history, and any history of
cancer in first-degree relatives, and also had donated a 40-ml blood
sample for genotyping. We extracted the clinical information from
the patients’ medical records of their co-morbid conditions, tumor
size, clinical stage, pathologic stage, histological type, tumor grade,
treatment type, tumor recurrence, survival, and tumor progression
for all the analyses. The median follow-up time was 11.8 months.
SNP selection and genotyping
A comprehensive panel of cancer-related genes including RGS
gene family was identified and classified in each specific pathway
according to their major reported functions. In the gene list,
seventeen genes in the RGS family (RGS 1–5, 7–14, 16, 18, 20,a n d
Figure 1. Kaplan-Meier estimates of the cumulative effect of unfavorable genotypes on NSCLC survival stratified by treatment.
Solid line represents low-risk group, carrying 0 unfavorable genotypes in chemotherapy (A) and 0-1 unfavorable genotypes in chemoradiotherapy
(B). Dashed line represents the medium-risk group, carrying 1-2 unfavorable genotypes in chemotherapy (A) and 2-3 unfavorable genotypes in
chemoradiotherapy (B). Dotted line represents high risk group, carrying 3-4 unfavorable genotypes in chemotherapy (A) and 4–5 unfavorable
genotypes in chemoradiotherapy (B). N: Number of Dead/Alive. MST: median survival time.
doi:10.1371/journal.pone.0021120.g001
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compiling the panel of genes and SNPs were reported previously
[55]. Genomic DNA was extracted from the peripheral blood
lymphocytes of the patients’ blood samples, and all the genotyping
work were performed according to the standard protocol provided
by Illumina Inc. Then the results of genotyping were automatically
generatedbytheIllumina’sBeadStudiosoftware.Finally,95SNPsin
the RGS pathway were selected and successfully genotyped in these
patients, as shown in Table S1 in the Supporting Information.
Statistical analysis
STATA statistical software (StataCorp LP, College Station, TX)
version 10.2 was used for the analysis of hazard ratios (HRs), P
values, median survival time (MST), P values for log-rank test and
Kaplan-Meier survival estimate. x
2 test (for categorical variables)
and Student’s t-test (for continuous variables) were used to assess
differences in variables between dead and alive patients. For each
SNP, the risk of death as a hazard ratio (HR) and 95% confidence
interval (CI) were estimated with the Cox proportional hazards
regression model. In addition, multivariate adjustment was used to
control for potential confounding factors (age, gender, ethnicity,
smoking status and pack-years, performance status, clinical stage,
and treatment). For each SNP, the genetic distribution were
assessed by three genetic models (dominant, recessive, and
additive), and the model with the smallest P value was selected
as the best-fitting model [56]. To validate the results, the bootstap
Figure 2. Survival tree analyses and Kaplan-Meier estimates of the significant RGS SNPs associated with survival.( A) Survival tree
analyses; 0:homozygous wild type genotype; 1:heterozygous genotype; 2:homozygous variant genotype. (B) and (C) represent the survival curves of
the risk group in chemotherapy group and chemoradiotherapy group; N: Number of Dead/Alive. MST: median survival time.
doi:10.1371/journal.pone.0021120.g002
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from the original data set, 100 bootstrap samples were generated.
We obtained the P value for each SNP among the dominant,
recessive, and additive models. The cumulative effects of different
genotypes were calculated by summing up the individual effects of
significant SNPs, that is, SNPs that showed significant association
in single-SNP analysis and also had a bootstrap P value ,0.05 at
least 70 times. We used Cox proportional hazards regression
model to estimate the HRs and 95% CIs. The Kaplan-Meier
method and the log-rank test were used to estimate their effects on
survival duration for these SNPs. Finally, the STREE program
(http://masal.med.yale.edu/stree/) was used to perform survival
tree analysis for the higher-order gene-gene interactions of the
SNPs. For these analyses, we only included SNPs that had been
validated internally by bootstrapping. A two-sided P,0.05 was
considered statistically significant.
Supporting Information
Table S1 NPs in the RGS pathway.
(DOC)
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